Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Enterprise Value (2020 - 2025)

Rani Therapeutics Holdings has reported Enterprise Value over the past 6 years, most recently at -$10.1 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$10.1 million for Q4 2025, down 347.41% from a year ago — trailing twelve months through Dec 2025 was -$10.1 million (down 347.41% YoY), and the annual figure for FY2025 was -$10.1 million, down 347.41%.
  • Enterprise Value for Q4 2025 was -$10.1 million at Rani Therapeutics Holdings, down from -$8.3 million in the prior quarter.
  • Over the last five years, Enterprise Value for RANI hit a ceiling of $17.2 million in Q3 2022 and a floor of -$88.4 million in Q4 2022.
  • Median Enterprise Value over the past 5 years was -$8.3 million (2025), compared with a mean of -$17.5 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 135.66% in 2023 and later plummeted 4870.77% in 2025.
  • Rani Therapeutics Holdings' Enterprise Value stood at -$43.3 million in 2021, then plummeted by 104.07% to -$88.4 million in 2022, then soared by 107.6% to $6.7 million in 2023, then tumbled by 133.68% to -$2.3 million in 2024, then crashed by 347.41% to -$10.1 million in 2025.
  • The last three reported values for Enterprise Value were -$10.1 million (Q4 2025), -$8.3 million (Q3 2025), and -$13.8 million (Q2 2025) per Business Quant data.